Notizie e Video - SOSEI CO LTD. SOLTF - Inglese - Pagina 3

Tokyo, Japan and Cambridge, UK, 25 October 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date: Friday, 10 November 2023 Time: 4 pm – 5 pm JST (7 am – 8 am GMT) Presenters: Chris Cargill, President and CEO Corporate presentation, vision, strategy and progress Dr. Matt Barnes, Head of UK R&D Progress in UK R&D Dr....

Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and development, is pleased to announce its President & CEO, Chris Cargill has won Executive of the Year for the second year running at the Citeline Pharma Intelligence Awards Japan 2023 held yesterday in Tokyo. The Citeline Pharma Intelligence Awards...

The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry leads on a second neurological disease target Tokyo, Japan and Cambridge, UK, 10 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) and PharmEnable Therapeutics, a UK drug discovery company, announce they have expanded their collaboration to apply...

Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on the Company’s scientific and early development strategy in support of its corporate objectives. Sosei Heptares’ SAB includes world-leading experts from academia and the pharmaceutical industry in the US and Europe, each of whom is highly regarded in their respective fields. These new...

NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditions NBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational...

HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan , London and Cambridge , UK, 10 August 20 2 3 – Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a...

Tokyo, Japan and Cambridge , UK, 4 August 20 2 3 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023. The full report can be found by clicking here . Chris Cargill, President & CEO of Sosei Heptares, commented: “We begin the second half of 2023 as a much enlarged, transformed and energized organization with a clear strategy for success, following the...

Tokyo, Japan and Cambridge , UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.” The conference will be held in person in Tokyo and virtually at 5pm JST (9am BST) on Thursday 20 July in Tokyo. The meeting is open to all...

T ransaction adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in Japan Lean , go-to-market commercial model , well positioned to scale rapidly to generate significant value from Japan and APAC (ex-China) geographic exp ansion Includes Japan and APAC (ex-China) rights 1 to two life-changing medicines with significant growth potential : PIVLAZ ® ( clazosentan; commercially available in Japan for cerebral vasospasm ; NHI sales of...

Tokyo, Japan and Cambri dge , U K, 1 1 J uly 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2023 on Friday, 4 August 2023. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO and Matt Barnes, President of Heptares Therapeutics and Head of UK R&D at 5 pm JST (9 am BST) on Friday, 4 August 2023. The webinar is open to all...

HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated with existing antipsychotic drugs Tokyo, Japan and Cambridge , UK, 3 Ju ly 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces it has dosed the first subject in a...

Tokyo, Japan and Cambridge , UK, 27 June 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1 receptor agonist candidate danuglipron for the treatment of diabetes and obesity and as a result has discontinued the development of lotiglipron – see Pfizer press announcement here . Both novel and orally available candidates were being advanced by Pfizer in Phase 2 clinical trials. Lotiglipron...

Tokyo, Japan and Cambridge , UK, 12 May 20 2 3 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023. The full report can be found here . Chris Cargill, President & CEO of Sosei Heptares, commented: “We are continuing to make good progress in building the foundation Sosei Heptares needs to become a leading international biopharmaceutical company headquartered in...

Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb , elected to the Company’s Board of Directors Candelle Chong promoted to Executive Vice President and Chief of Staff , previously Senior Vice President , Corporate Strategy Tokyo, Japan and Cambridge , UK, 23 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces the election of...

Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has changed the market on which the Company's shares are listed on the Tokyo Stock Exchange, Inc. (“TSE”) from the Growth Market segment to the Prime Market segment, effective today. Chris Cargill, President & CEO of Sosei Heptares, commented: “We believe...

Tokyo, Japan and Cambridge , UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, is pleased to announce it has received approval from the Tokyo Stock Exchange, Inc. (“TSE”) to change the market on which the Company's shares are listed from the Growth Market segment to the Prime Market segment, effective March 15, 2023. We are deeply grateful to our...

Tokyo, Japan and Cambridge , UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2022. The full report can be found here . Chris Cargill, President & CEO of Sosei Heptares, commented: “2022 was a very important and successful year for...

TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, will announce its earnings results and present operational highlights for the 12 months ended 31 December 2022 on Tuesday, 14 February 2023. The Company will host a webinar presentation in-person and virtually for institutional investors, securities analysts...

TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero Bio Phase 1 study in healthy volunteers expected to begin in Q1 2023 with support from a US$5.3M grant from the US National Institute on Drug Abuse (NIDA) Tempero Bio was created by Aditum Bio in collaboration with Sosei Heptares in 2020 to advance the clinical development of mGluR5 NAM candidates to develop...

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trials Dosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10 million to Sosei Heptares TOKYO and CAMBRIDGE, United Kingdom, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by Pfizer that...